Extrinsic coagulation pathway activation and metalloproteinase-2/TIMPs system are related to oxidative stress and atherosclerosis in hemodialysis patients

Summary

Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs), together with extrinsic coagulation pathway activation and increased oxidative stress (SOX) have all been implicated as important factors in atherosclerosis and vascular remodelling. The aim of the present study was to investigate whether the MMPs/TIMPs system is associated with activation of the extrinsic coagulation pathway in conditions of increased SOX in hemodialysis (HD) patients. In HD patients, with and without cardiovascular disease (CVD), and in controls, we compared pre-dialysis levels of MMP-2, MMP-9,TIMP-1,TIMP-2; the markers of extrinsic coagulation pathway-tissue factor (TF) and its inhibitor (TFPI), prothrombin fragment F1+2 (F1+2); a marker of SOX-Cu/Zn superoxide dismutase (Cu/Zn SOD) and a surrogate of atherosclerotic disease-intima media thickness (IMT). Hemodialysis patients, particularly those with CVD, showed a significant increase in values of MMP-2/TIMPs, markers of the extrinsic coagulation pathway, Cu/Zn SOD and IMT as compared to controls. The markers of coagulation activation positively correlated with the MMP-2/TIMPs system, whereas they did not correlate with MMP-9. In addition, both MMP-2/TIMPs as well as extrinsic coagulation parameters were related to the prevalence of increased SOX, IMT and CVD. Multiple stepwise regression analysis showed that low TIMP-2 followed by increased Cu/Zn SOD and MMP-2 levels independently and significantly predicted elevated IMT on maintenance HD patients. In conclusion, our data suggest that the MMP-2/TIMPs system and an activated extrinsic coagulation pathway could cooperate in conditions of elevated SOX and could influence arterial remodeling resulting in the presence of CVD in haemodialysis patients.

Keywords

Atherosclerosis - coagulation activation - MMPs/TIMPs system - hemodialysis - oxidative stress

• References

• 1 Amann K, Ritz C, Adamczak M. et al. Why is coronary heart disease of uraemic patients so frequent and so devastating?. Nephrol Dial Transplant 2003; 18: 631-40.
• 2 Boaz M, Green M, Fainauru M. et al. Oxidative stress and cardiovascular disease in hemodialysis. Clin Nephrol 2001; 55: 93-100.
• 3 Himmelfarb J, Stenvinkel P, Ikizler TA. et al. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002; 62: 1524-38.
• 4 Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis. The good, the bad, and the ugly. Circ Res 2002; 90: 251-62.
• 5 Pasterkamp G, Schoneveld AH, Hijnen DJ. et al. Atherosclerotic arterial remodeling and the localization of macrophages and matrix metalloproteases 1, 2 and 9 in the human coronary artery. Atherosclerosis 2000; 150: 245-53.
• 6 Zaltsman AB, George SJ, Newby AC. Increased secretion of tissue inhibitors of metalloproteinases 1 and 2 from the aortas of cholesterol fed rabbits partially counterbalances increased metalloproteinase activity. Arterioscler Thromb Vasc Biol 1997; 19: 1700-7.
• 7 Baramova EN, Bajou K, Remacle A. et al. Involvement of PA/plasmin system in the processing of pro-MMP-9 and in the second step of pro-MMP-2 activation. FEBS Lett 1997; 405: 157-62.
• 8 Pei D, Weiss SJ. Transmembrane-deletion mutants of the membrane-type matrix metalloproteinase-1 process progelatinase A and express intrinsic matrix-degrading activity. J Biol Chem 1996; 271: 9135-40.
• 9 Galis ZS, Kranzhöfer JWFenton. et al. Thrombin promotes activation of matrix metalloproteinase-2 produced by cultured vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1997; 17: 483-9.
• 10 Doshi SN, Marmur JD. Evolving role of tissue factor and its pathway inhibitor. Crit Care Med 2002; 30 (Suppl. 05) S241-S250.
• 11 Kaikita K, Takeya M, Ogawa H. et al. Colocalization of tissue factor and tissue factor pathway inhibitor in coronary atherosclerosis. J Pathol 1999; 188: 180-8.
• 12 Singh R, Pan S, Mueske CS. et al. Role for tissue pathway in murine model of vascular remodeling. Circ Res 2001; 89: 71-6.
• 13 Pawlak K, Borawski J, Naumnik B. et al. Relationship between oxidative stress and extrinsic coagulation pathway in haemodialyzed patients. Thromb Res 2003; 109: 247-51.
• 14 Pawlak K, Naumnik B, Brzósko S. et al. Oxidative stress-a link between endothelial injury, coagulation activation and atherosclerosis in haemodialysis patients. Am J Nephrol 2004; 24: 154-61.
• 15 Chou F-P, Chu S-C, Chen M-C. et al. Effect of hemodialysis on the plasma level of type IV collagenases and their inhibitors. Clin Biochem 2002; 35: 383-8.
• 16 Chandra J, Samali A, Orrenius S. Triggering and modulation of apoptosis by oxidative stress. Free Radic Biol Med 2000; 29: 323-33.
• 17 Mates JM, Perez-Gomez C, Nunez de Castro IN. Antioxidant enzymes and human diseases. Clin Biochem 1999; 32: 595-603.
• 18 Schock BC, Sweet DG, Ennis M. et al. Oxidative stress and increased type-IV collagenase levels in bronchoalveolar lavage fluid from newborn babies. Pediatr Res 2001; 50: 29-33.
• 19 Gonzalez W, Fontaine V, Pueyo ME. et al. Molecular plasticity of vascular wall during N(G)-nitro-L-arginine methyl ester-induced hypertension: modulation of proinflammatory signals. Hypertension 2000; 36: 103-9.
• 20 Yang ZZ, Zou AP. Homocysteine enhances TIMP-1 expression and cell proliferation associated with NADH oxidase in rat mesangial cells. Kidney Int 2003; 63: 1012-20.
• 21 Mezzano D, Pais EO, Aranda E. et al. Inflammation, not hyperhomocysteinemia, is related to oxidative stress and hemostatic and endothelial dysfunction in uremia. Kidney Int 2001; 60: 1844-50.
• 22 De Cristofaro R, Rocca B, Marchioli R. et al. Plasma protein oxidation is associated with an increase of procoagulant markers causing an imbalance between pro- and anticoagulant pathways in healthy subjects. Thromb Haemost 2002; 87: 58-67.
• 23 Serradell M, Diaz-Ricart M, Cases A. et al. Uremic medium disturbs the hemostatic balance of cultured human endothelial cells. Thromb Haemost 2001; 86: 1099-105.
• 24 Zucker S, Conner C, DiMassmo BI. et al. Thrombin induces the activation of progelatinase A in vascular endothelial cells. Physiologic regulation of angiogenesis. J Biol Chem 1995; 270: 23730-8.
• 25 Fernandez-Patron C, Zhang Y, Radomski MW. et al. Rapid release of matrix metalloproteinase (MMP-2) by thrombin in the rat aorta: modulation by protein tyrosine kinase/phosphatase. Thromb Haemost 1999; 82: 1353-7.
• 26 Marin F, Roldan V, Climent V. et al. Is thrombogenesis in atrial fibrillation related to matrix metalloproteinase-1 and its inhibitor, TIMP-1?. Stroke 2003; 34: 1181-6.
• 27 Kabayashi S, Inoue N, Azumi H. et al. Expressional changes of the vascular antioxidant system in atherosclerotic coronary arteries. J Atheroscler Thromb 2002; 09: 184-90.
• 28 Galis ZS, Sukluva GK, Lark MW. et al. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994; 94: 2493-503.
• 29 Kai H, Ikeda H. Yasukawa et al. Peripheral blood levels of matrix metalloproteinases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 1998; 32: 368-72.
• 30 Rajagopalan S, Meng XP, Ramasamy S. et al. Reactive oxygen species produced by macro-phage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro . J Clin Invest 1996; 98: 2572-9.
• 31 George SJ, Angelini GD, Newby AC. et al. Adenovirus mediated transfer of human TIMP-1 gene inhibits smooth muscle cells migration and neointima formation in human saphenous vein. Hum Gene Ther 1998; 09: 867-77.
• 32 Beaudeux JL, Giral P, Bruckert E. et al. Serum matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 as potential markers of carotid atherosclerosis in infraclinical hyperlipidemia. Atherosclerosis 2003; 169: 139-46.
• 33 Falciani M, Gori AM, Fedi S. et al. Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patients. Thromb Haemost 1998; 79: 495-9.
• 34 Vila V, Martinez-Sales V, Reganon E. et al. Effects of unfractionated and low molecular weight heparins on plasma levels of hemostatic factors in patients with acute coronary syndromes. Haematologica 2001; 86: 729-34.